Kevin Starr
Keine laufenden Positionen mehr
Vermögen: 6 Mio $ am 31.03.2024
Profil
Kevin Paul Starr ist ein Geschäftsmann, der Third Rock Ventures LLC und Decibel Therapeutics, Inc. gegründet hat und 5 verschiedene Unternehmen geleitet hat. Gegenwärtig ist er Vorsitzender bei SAGE Therapeutics, Inc. und Partner bei Third Rock Ventures LLC. In seiner bisherigen Laufbahn hatte Herr Starr die Position des Chairman & Chief Executive Officer von Decibel Therapeutics, Inc. inne, des Chairman von Agios Pharmaceuticals, Inc. des Chairman von Afferent Pharmaceuticals, Inc. des Director von Ember Therapeutics, Inc. des Chief Operating & Financial Officer von Millennium Pharmaceuticals, Inc. des Principal von Digital Equipment Corp. und des Controller von Biogen MA, Inc. Herr Starr erwarb einen Bachelor-Abschluss am Colby College und einen Master-Abschluss am Boston College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SAGE THERAPEUTICS, INC.
0,53% | 30.11.2023 | 320 659 ( 0,53% ) | 6 Mio $ | 31.03.2024 |
Ehemalige bekannte Positionen von Kevin Starr
| Unternehmen | Position | Ende |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Chairman | 05.01.2024 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Founder | 02.01.2021 |
| MYOKARDIA, INC. | Director/Board Member | 06.03.2018 |
| ALNYLAM PHARMACEUTICALS, INC. | Director/Board Member | 01.03.2018 |
| DECIBEL THERAPEUTICS, INC. | Chief Executive Officer | 13.07.2016 |
Ausbildung von Kevin Starr
| Boston College | Graduate Degree |
| Colby College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| SAGE THERAPEUTICS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
| Digital Equipment Corp. | Electronic Technology |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Konarka Technologies, Inc.
 Konarka Technologies, Inc. SemiconductorsElectronic Technology Konarka Technologies, Inc. developed nano-enabled polymer photovoltaic materials. The company was founded in 2001 and was headquartered in Lowell, MA. | Electronic Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Vitae Pharmaceuticals LLC
 Vitae Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vitae Pharmaceuticals LLC is a clinical-stage bio-pharmaceutical company, which engages in discovering and developing novel, small molecule drugs for diseases, including chronic kidney disease, diabetes and Alzheimer's disease, and autoimmune disorders, acute coronary syndrome, and immuno-oncology. The company was founded by John J. Baldwin, Bartosz A. Grzybowski, George M. Whitesides, and Eugene Shakhnovich on May 21, 2001 and is headquartered in Fort Washington, PA. | Health Technology |
PanOptica, Inc.
 PanOptica, Inc. Pharmaceuticals: MajorHealth Technology PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ. | Health Technology |
Ember Therapeutics, Inc. /Old/
 Ember Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Ember Therapeutics, Inc. provides treatment for metabolic disorders and obesity diseases. Its products target brown fat biology and mechanisms of selective insulin sensitization. The company was founded by Bruce M. Spiegelman, Patrick R. Griffin and Ronald C. Kahn in 2011 and is headquartered in New York, NY. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
